Inexium

Esomeprazole, the active ingredient in Inexium, is a proton pump inhibitor presented as an intravenous solution for intravenous use. It provides rapid reduction of gastric acid secretion and is indicated for the treatment of gastro‑oesophageal reflux disease, erosive esophagitis and peptic ulcer disease, particularly in patients who cannot take oral therapy.

GNH USA supplies Inexium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Esomeprazole is a proton pump inhibitor used to manage conditions associated with excess gastric acid.

- Gastro‑oesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and regurgitation. - Erosive esophagitis: promotes healing of acid‑induced esophageal lesions. - Peptic ulcer disease: facilitates ulcer healing by maintaining a low‑acid gastric environment.

Adverse reactions reported with intravenous esomeprazole are generally consistent with the class of proton pump inhibitors.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools occurring during treatment. - Nausea: transient feeling of queasiness. - Injection site reactions: erythema or pain at the infusion site.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis associated with altered gut flora. - Acute interstitial nephritis: inflammation of kidney interstitium. - Anaphylaxis: life‑threatening allergic response.

When using intravenous esomeprazole, clinicians should observe several precautionary measures to ensure safety and efficacy. - Assess renal function: adjust use in patients with severe renal impairment. - Monitor electrolytes: watch for hypomagnesemia during prolonged therapy. - Evaluate for infection: consider risk of Clostridioides difficile colitis. - Use cautiously in pregnancy: limited data, weigh benefits against potential risks. - Store at ambient temperature: keep below 25 °C, protect from light and moisture in original packaging.

Esomeprazole may alter the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole: reduced absorption leading to loss of antifungal efficacy. - Atazanavir: decreased plasma concentrations compromising HIV therapy. - Warfarin: potential increase in anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Clopidogrel: reduced activation may diminish antiplatelet activity. - Digoxin: increased serum levels may require dose adjustment. - Methotrexate: higher exposure can enhance toxicity, especially at high doses.